89bio ETNB 深 滬
等待開盤 09-05 09:30:00 美东时间
8.57
-0.670
-7.25%
華盛通- 最 高9.47
- 今 開9.36
- 成交量 120.83万股
- 最 低 8.455
- 昨 收 9.24
- 總市值 12.68亿
- 52周最高 11.84
- 市盈率 靜 --
- 換手率 0.82%
- 52周最低 4.16
- 委 比 -78.14%
- 總股本 1.48亿
- 歷史最高 47.253
- 量 比 0.85
- 振 幅 10.98%
- 歷史最低 2.00
- 每 手 1
- 風險率 1.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Assumes 89bio at Buy, Announces Price Target of $32
HC Wainwright & Co. analyst Andrew S. Fein assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $32.
09-04 19:13
89bio to Participate in Upcoming Investor Conferences
89bio, a biopharmaceutical company developing therapies for liver and cardiometabolic diseases, announced that its management will participate in three investor conferences in September 2025. These include fireside chats at Citi’s Biopharma Back to School Conference on September 3 and Cantor Global Healthcare Conference on September 4, and one-on-one meetings at H.C. Wainwright's Global Investment Conference on September 8. Webcasts of the firesi...
08-28 20:05
美股大行评级 | 潜在涨幅17.9%！Stifel维持英伟达"买入"评级，目标价升至212美元；美银首予Figma"中性"评级，目标价85美元
今日重点评级关注：Stifel：维持英伟达"买入"评级，目标价从202美元升至212美元；蒙特利尔银行：维持Sabra Health Care REIT"与大市齐平"评级，目标价从19美元升至22美元
08-26 10:29
B of A Securities Maintains Buy on 89bio, Lowers Price Target to $29
B of A Securities analyst Alexandria Hammond maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $30 to $29.
08-26 00:49
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
89Bio Inc. Faces Financial Uncertainty Amid Potential U.S. Tax Law Changes
89Bio Inc (ETNB) has disclosed a new risk, in the Taxation & Government Inc...
08-10 14:00
RBC Capital Maintains Sector Perform on 89bio, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams maintains 89bio (NASDAQ:ETNB) with a Sector Perform and lowers the price target from $12 to $11.
08-09 01:16
89bio Q2 EPS $(0.71) Misses $(0.49) Estimate
89bio (NASDAQ:ETNB) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.49) by 43.72 percent. This is a 47.92 percent decrease over losses of $(0.48) per share from the same
08-08 04:54
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
89bio reported Q2 2025 financial results with $561.2 million in cash and highlighted progress in their Phase 3 trials for pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Topline data for ENLIGHTEN-Fibrosis (MASH, F2-F3) and ENLIGHTEN-Cirrhosis (MASH, F4) are expected in 2027 and 2028, respectively, while ENTRUST (SHTG) data is anticipated in Q1 2026. The company emphasized pegozaferm...
08-07 20:05
新浪财经ESG：ETNB MSCI（明晟）ESG评级调降至A
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-19 07:00
